Progressive clinical effects of the combination omalizumab and HDM – allergen immunotherapy in asthma

References

• Głobińska A, Boonpiyathad T, Satitsuksanoa P, Kleuskens M, van de Veen W, Sokolowska M, Akdis M. Mechanisms of allergen-specific immunotherapy: diverse mechanisms of immune tolerance to allergens. Ann Allergy Asthma Immunol. 2018;121(3):306–312. doi:10.1016/j.anai.2018.06.026.
   PubMed Web of Science ®Google Scholar
• Pfaar O, Agache I, de Blay F, Bonini S, Chaker AM, Durham SR, Gawlik R, Hellings PW, Jutel M, Kleine-Tebbe J, et al. Perspectives in allergen immunotherapy: 2019 and beyond. Allergy. 2019;74(S108):3–25. doi:10.1111/all.14077.
   PubMedGoogle Scholar
• Dhami S, Kakourou A, Asamoah F, Agache I, Lau S, Jutel M, Muraro A, Roberts G, Akdis CA, Bonini M, et al. Allergen immunotherapy for allergic asthma: a systematic review and meta-analysis. Allergy. 2017;72(12):1825–1848. doi:10.1111/all.13208.
   PubMed Web of Science ®Google Scholar
• Agache I, Lau S, Akdis CA, Smolinska S, Bonini M, Cavkaytar O, Flood B, Gajdanowicz P, Izuhara K, Kalayci O, et al. Eaaci guidelines on allergen immunotherapy: house dust mite-driven allergic asthma. Allergy. 2019;74(5):855–873. doi:10.1111/all.13749.
   PubMed Web of Science ®Google Scholar
• Lommatzsch M, Brusselle GG, Canonica GW, Jackson DJ, Nair P, Buhl R, Virchow JC. Disease-modifying anti-asthmatic drugs. Lancet. 2022;399(10335):1664–1668. doi:10.1016/S0140-6736(22)00331-2.
   PubMed Web of Science ®Google Scholar
• Durham SR, Shamji MH. Allergen immunotherapy: past, present and future. Nat Rev Immunol. 2023;23(5):317–328. doi:10.1038/s41577-022-00786-1.
   PubMed Web of Science ®Google Scholar
• Pfützner W, Schuppe M. Use of biologics in allergen immunotherapy. Allergol Select. 2021;5(01):108–118. doi:10.5414/ALX02206E.
   PubMedGoogle Scholar
• Lombardi C, Canonica GW, Passalacqua G. Allergen immunotherapy as add-on to biologic agents. Curr Opin Allergy Clin Immunol. 2018;18(6):502–508. doi:10.1097/ACI.0000000000000479.
   PubMed Web of Science ®Google Scholar
• Dantzer JA, Wood RA. Update on omalizumab in allergen immunotherapy. Curr Opin Allergy Clin Immunol. 2021;21(6):559–568. doi:10.1097/ACI.0000000000000781.
   PubMed Web of Science ®Google Scholar
• Malipiero G, Melone G, Puggioni F, Pawankar R, Heffler E, Paoletti G. Allergen immunotherapy and biologics in respiratory allergy: friends or foes? Curr Opin Allergy Clin Immunol. 2021;21(1):16–23. doi:10.1097/ACI.0000000000000707.
   PubMed Web of Science ®Google Scholar
• Global Initiative for Asthma. Gina main report; 2022 [accessed 2023 May 2]. https://ginasthma.org/gina-reports.
   Google Scholar
• Kopp MV, Hamelmann E, Bendiks M, Zielen S, Kamin W, Bergmann KC, Klein C, Wahn U, DUAL Study Group. Transient impact of omalizumab in pollen allergic patients undergoing specific immunotherapy. Pediatr Allergy Immunol. 2013;24(5):427–433. doi:10.1111/pai.12098.
   PubMed Web of Science ®Google Scholar
• Kopp MV, Hamelmann E, Zielen S, Kamin W, Bergmann KC, Sieder C, Stenglein S, Seyfried S, Wahn U, DUAL Study Group. Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma. Clin Exp Allergy. 2009;39(2):271–279. doi:10.1111/j.1365-2222.2008.03121.x.
   PubMed Web of Science ®Google Scholar
• Stelmach I, Majak P, Jerzyńska J, Bojo M, Cichalewski Ł, Smejda K. Children with severe asthma can start allergen immunotherapy after controlling asthma with omalizumab: a case series from Poland. Arch Med Sci. 2015;11(4):901–904. doi:10.5114/aoms.2015.48546.
   PubMed Web of Science ®Google Scholar
• Massanari M, Nelson H, Casale T, Busse W, Kianifard F, Geba GP, Zeldin RK. Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma. J Allergy Clin Immunol. 2010;125(2):383–389. doi:10.1016/j.jaci.2009.11.022.
   PubMed Web of Science ®Google Scholar
• Kuehr J, Brauburger J, Zielen S, Schauer U, Kamin W, Von Berg A, Leupold W, Bergmann KC, Rolinck-Werninghaus C, Gräve M, et al. Efficacy of combination treatment with anti-ige plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J Allergy Clin Immunol. 2002;109(2):274–280. doi:10.1067/mai.2002.121949.
   PubMed Web of Science ®Google Scholar
• Wood RA, Kim JS, Lindblad R, Nadeau K, Henning AK, Dawson P, Plaut M, Sampson HA. A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow’s milk allergy. J Allergy Clin Immunol. 2016;137(4):1103–1110.e11. doi:10.1016/j.jaci.2015.10.005.
   PubMed Web of Science ®Google Scholar
• Andorf S, Purington N, Block WM, Long AJ, Tupa D, Brittain E, Rudman Spergel A, Desai M, Galli SJ, Nadeau KC, et al. Anti-ige treatment with oral immunotherapy in multifood allergic participants: a double-blind, randomised, controlled trial. Lancet Gastroenterol Hepatol. 2018;3(2):85–94. doi:10.1016/S2468-1253(17)30392-8.
   PubMed Web of Science ®Google Scholar
• Rerinck H, Rueff F, Przybilla B. Recurrent severe anaphylactic reactions to venom immunotherapy (VIT): omalizumab induces tolerance. J Allergy Clin Immunol. 2008;121(2):S29–S29. doi:10.1016/j.jaci.2007.12.118.
   Web of Science ®Google Scholar
• Palgan K, Bartuzi Z, Gotz-Zbikowska M. Treatment with a combination of omalizumab and specific immunotherapy for severe anaphylaxis after a wasp sting. Int J Immunopathol Pharmacol. 2014;27(1):109–112. doi:10.1177/039463201402700114.
   PubMed Web of Science ®Google Scholar
• Abdel-Gadir A, Schneider L, Casini A, Charbonnier LM, Little SV, Harrington T, Umetsu DT, Rachid R, Chatila TA. Oral immunotherapy with omalizumab reverses the Th2 cell-like programme of regulatory T cells and restores their function. Clin Exp Allergy. 2018;48(7):825–836. doi:10.1111/cea.13161.
   PubMed Web of Science ®Google Scholar
• Bożek A, Fischer A, Bogacz-Piaseczynska A, Canonica GW. Adding a biologic to allergen immunotherapy increases treatment efficacy. ERJ Open Res. 2023;9(2):00639–2022. doi:10.1183/23120541.00639-2022.
   PubMedGoogle Scholar
• Valdesoiro-Navarrete L, León ME, Rodríguez M, Indiveri M, Ayats R, Larramona H, González MG, de la Cruz ÒA, García MB. Combination therapy of specific aeroallergens immunotherapy and omalizumab, in children with severe asthma. Allergol Immunopathol (Madr). 2022;50(2):1–6. doi:10.15586/aei.v50i2.469.
   Web of Science ®Google Scholar
• Potapova E, Bordas-Le Floch V, Schlederer T, Vrtala S, Huang HJ, Canonica GW, Valenta R, Matricardi PM, Mascarell L. Molecular reactivity profiling upon immunotherapy with a 300 IR sublingual house dust mite tablet reveals marked humoral changes towards major allergens. Allergy. 2022;77(10):3084–3095. doi:10.1111/all.15327.
   PubMed Web of Science ®Google Scholar
• Nittner-Marszalska M, Kopeć A, Foks-Ciekalska A, Lata A, Bogacz-Piaseczyńska A, Rosiek-Biegus M, Zajac M, Bożek A. Monitoring of molecular profiling of allergen-antibody responses in HDM-immunotherapy patients. Hum Vaccin Immunother. 2022;18(7):2148815. doi:10.1080/21645515.2022.2148815.
   PubMedGoogle Scholar